###begin article-title 0
###xml 14 58 14 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 codon 72 and intron 3 duplication 16bp </italic>
Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 266 275 266 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Pro </italic>
###xml 279 292 279 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 Ins16bp </italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
TP53 is one of major tumour suppressor genes being essential in preservation of genome integrity. Two very common polymorphisms have been demonstrated to contribute to cancer susceptibility and tumour behaviour. The purpose of this study was to evaluate the role of Arg72Pro and PIN3 Ins16bp polymorphisms in TP53 gene as genetic susceptibility and predictive markers to breast cancer.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 78 92 78 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg72Pro </italic>
###xml 96 109 96 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 Ins16bp </italic>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
We analysed DNA samples from 264 breast cancer patients and 440 controls, for TP53 Arg72Pro and PIN3 Ins16bp polymorphisms using PCR-RFLP.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2A2 </italic>
###xml 337 349 337 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg-A2 </italic>
###xml 497 502 497 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 17 22 <span type="species:ncbi:9606">women</span>
###xml 102 107 <span type="species:ncbi:9606">women</span>
We observed that women with A2A2 genotype have increased risk for developing breast cancer, either in women with or without familial history (FH) of the disease (OR = 4.40, 95% CI 1.60-12.0; p = 0.004; OR = 3.88, 95% CI 1.18-12.8; p = 0.026, respectively). In haplotype analysis, statistically significant differences were found between TP53 Arg-A2 haplotype frequencies and familial breast cancer cases and the respective control group (OR = 2.10, 95% CI 1.08-4.06; p = 0.028). Furthermore, both TP53 polymorphisms are associated with higher incidence of lymph node metastases.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 21 39 21 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 PIN3 Ins16bp </italic>
Our findings suggest TP53 PIN3 Ins16bp polymorphism as a real risk modifier in breast cancer disease, either in sporadic and familial breast cancer. Furthermore, both TP53 polymorphisms are associated with higher incidence of lymph node metastases.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 382 387 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 593 594 593 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 871 876 871 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 944 945 944 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 946 947 946 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 953 958 953 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1138 1139 1138 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1278 1279 1278 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1280 1282 1280 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1285 1290 1285 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Breast cancer have been associated with well-established risk factors, such as high estrogen exposure, environmental factors (e. g. diet and ionizing radiation) and family history [1,2]. Family history of breast cancer is a particularly important high risk factor for this disease. Two genes were identified as the major susceptibility genes in high risk families, namely BRCA1 and BRCA2. However, these genes account for only a minority of the overall family risk of breast cancer [3]. Furthermore, approximately only 10% of all breast cancer cases exhibit a familial pattern of incidence [4,5]. In this way, the remaining familial and sporadic risk may be due to common low to moderate penetrance genetic variants, which are also referred as genetic polymorphisms. One strong candidate for genetic susceptibility factor to familial and/or sporadic breast cancer is the TP53 gene. This gene is frequently somatically mutated in breast cancer [6,7] and TP53 germline mutations are associated with increased risk for developing diverse malignancies, including 25-30% of hereditary breast cancer cases associated with Li-Fraumeni syndrome [8]. Furthermore, based on its pivotal role in DNA damage repair and its physical and functional interactions with BRCA1 and BRCA2 proteins [9,10], TP53 seems to be a strong candidate breast cancer predisposition.
###end p 11
###begin p 12
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
The TP53 tumour suppressor gene, also designated the guardian of the genome, is essential in preservation of genome integrity. From the numerous biological functions of p53 protein, inhibition of cell cycle progression, DNA repair and apoptosis are the major cellular pathways where it is involved [6].
###end p 12
###begin p 13
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
TP53 gene mutations are widely detected in breast cancer, being correlated with specific clinical phenotypes [11,12].
###end p 13
###begin p 14
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 349 357 349 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Pro</italic>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 586 591 586 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 597 609 597 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 Ins16bp</italic>
###xml 26 31 <span type="species:ncbi:9606">human</span>
Predisposition to several human cancers has been associated with genetic polymorphisms, which may represent an important contribution to cancer susceptibility and tumour behaviour [13-16]. Several polymorphisms have been identified within TP53 gene, both in non-coding and coding regions [17]. One of the most well studied TP53 gene polymorphism is Arg72Pro, located in codon 72 on exon 4, leading to arginine-proline substitution, which in its turn results in a structural alteration of the protein [18]. Another common polymorphism is 16 base pair (bp) duplication in intron 3 of the TP53 gene (PIN3 Ins16bp).
###end p 14
###begin p 15
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
In this case-control study, we hypothesize that the two common polymorphisms of TP53 gene play a role either apoptosis, cell cycle control efficiency, as well as DNA repair capacity, which ultimately may contribute to an increase of breast cancer susceptibility within familial and/or sporadic cases, as well as represent an additional tool for prognosis prediction.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Study Population
###end title 17
###begin p 18
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1111 1123 1109 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/BRCA2 </italic>
###xml 1147 1149 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 334 342 <span type="species:ncbi:9606">patients</span>
###xml 746 751 <span type="species:ncbi:9606">women</span>
###xml 1277 1282 <span type="species:ncbi:9606">women</span>
###xml 1552 1557 <span type="species:ncbi:9606">women</span>
###xml 1731 1736 <span type="species:ncbi:9606">women</span>
###xml 1815 1823 <span type="species:ncbi:9606">patients</span>
###xml 1973 1985 <span type="species:ncbi:9606">participants</span>
We analysed a total of 264 DNA breast cancer cases: 73 unrelated familial breast cancer cases were selected from the Oncology and Surgical Departments from S. Joao Hospital at Porto and Vigo Hospital, and 191 unrelated sporadic breast cancer cases were recruited from IPO-Porto (Oncology Portuguese Institute), during 1998-2003, from patients that were receiving treatment. All cases were histological confirmed at the Department of Pathology. Clinico-pathological parameters were obtained when possible from hospital clinical records. Familial case group presented a mean age of 42.07 years, with an age range of 24-77 years. The high-risk familial breast cancer group, also designated by us as family history (FH) breast cancer cases, included women with the follow features, based on the Breast Cancer Linkage Consortium criteria [19]: early onset (</=40 years) and/or bilaterality; or more than three cases of breast cancer in the family; or more than one case of ovarian cancer in the family; or more than two first-degree relatives involved; or male breast cancer. These high-risk breast cancer cases are BRCA1/BRCA2 mutations non-carriers [20]. Sporadic cases group (with no presence of FH) presented a mean age of 53.41 years, with an age range of 41-88 years. Control women were randomly selected from blood banks in the same region during the same time period as the cases were collected. The selection criteria include no prior history of cancer, and controls were frequency matched to the cases by age (+/- 5 years). A total of 440 healthy women presenting a median age of 42.29 years and an age range of 21-85 years, were used as control group of familial breast cancer cases. From the above control group 216 healthy women were selected according to the age of diagnosis of the sporadic breast cancer patients group (higher than 40 years), with a median age of 53.05 and an age range of 41-85, being used as control group of sporadic breast cancer cases. All participants provided informed consent. Ethical approval was obtained by the specific institutions ethical committees.
###end p 18
###begin title 19
Laboratory Methods
###end title 19
###begin p 20
###xml 78 82 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 198 212 196 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg72Pro </italic>
###xml 557 566 537 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bsh1236I </italic>
###xml 699 703 673 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 921 939 893 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 PIN3 Ins16bp </italic>
###xml 1321 1325 1275 1277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1427 1430 1379 1382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A1 </italic>
###xml 1518 1521 1470 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2 </italic>
Genomic DNA was isolated from lymphocytes of peripherical blood using Puregene(R) DNA Purification Kit (Gentra Systems, Minneapolis, USA). All the polymorphisms were assessed by PCR-RFLP technique. TP53 Arg72Pro polymorphism (rs1042522) was detected by amplifying genomic DNA with the forward primer 5'-GAA GAC CCA GGT CCA GAT GA-3' and the reverse primer 5'-CTG CCC TGG TAG GTT TTC TG-3'. The PCR amplification parameters were 32 cycles each of 30 sec at 94degreesC, 30 sec at 54degreesC, and 30 sec at 72degreesC. The 152 bp PCR product was digested with Bsh1236I (Fermentas, Ontario, Canada) at 37degreesC overnight. Digested products were separated by electrophoresis in a 3% agarose gel (Seakem(R) LE Agarose, Rockland, USA) and visualized by ethidium bromide staining. Wild type alleles resulted in 50 and 102 bp fragments and the variant alleles resulted in 152 bp fragment following restriction enzyme digestion. TP53 PIN3 Ins16bp polymorphism (rs17878362) was detected by amplifying genomic DNA with the forward primer 5'-CTG AAA ACA ACG TTC TGG TA-3' and the reverse primer 5'-AAG GGG GAC TGT AGA TGG GTG-3'. The PCR amplification parameters were 32 cycles each of 30 sec at 94degreesC, 30 sec at 60degreesC, and 30 sec at 72degreesC. The PCR product was separated by electrophoresis in a 4% agarose gel (Seakem(R) LE Agarose, Rockland, USA) and visualized by ethidium bromide staining. Wild type alleles, designated A1 allele (no duplication) resulted in 119 bp fragment and the variant alleles, designated A2 allele (with 16 bp duplication) resulted in 135 bp fragment.
###end p 20
###begin p 21
To ensure quality control of all genotyping results, 10% of the samples was randomly selected and sequenced using an ABI automated sequencer. We obtained a 98% of concordance between the genotyping results acquire by the two methods.
###end p 21
###begin title 22
Statistical Analysis
###end title 22
###begin p 23
###xml 436 441 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 586 591 584 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 982 984 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
Analysis of data was performed using the computer software SPSS version 14.0 (SPSS Inc., Chicago, USA). Chi-square (chi2 test) analysis was used to compare categorical variables. Whenever necessary, the Fisher test was used when number of samples was equal or inferior to 5. A 5% level of significance was used in the analysis. The Odds Ratio (OR) and its 95% confidence interval (CI) were calculated to measure the association between TP53 polymorphic genotypes and breast cancer risk. Logistic regression analysis was used to calculate the adjusted OR and 95% CI for the influence of TP53 genotypes in the risk of breast cancer, adjusted for age and/or FH. Whenever appropriate, the observed number of each genotype in control groups were compared with that expected for a population in the Hardy-Weinberg Equilibrium by using a goodness of fit chi2 test. The frequencies of expected haplotypes were estimated by using the statistical methodologies implemented by HPlus software [21], which infers haplotypes based on expectation-maximization with a modified progressive ligation computational algorithm. The nonparametric test, Kruskal-Wallis test, was used to compare mean age of diagnosis between the different genotype polymorphisms.
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 48 61 48 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 Ins16bp </italic>
###xml 114 123 114 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Pro </italic>
###xml 127 140 127 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 Ins16bp </italic>
###xml 272 281 272 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Pro </italic>
The distribution of the genotype frequencies in PIN3 Ins16bp polymorphisms among control group (p = 0.478) and in Arg72Pro and PIN3 Ins16bp among control subgroup (p = 0.082 and p = 0.294) is in agreement with those expected under Hardy-Weinberg equilibrium, excepted for Arg72Pro in the overall control group (p = 0.013).
###end p 25
###begin p 26
###xml 11 25 11 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg72Pro </italic>
###xml 90 98 90 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Arg</italic>
###xml 100 109 100 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Pro </italic>
###xml 113 122 113 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pro72Pro </italic>
###xml 234 240 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">72Arg </italic>
###xml 280 286 280 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">72Pro </italic>
###xml 373 387 373 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg72Pro </italic>
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Concerning TP53 Arg72Pro polymorphism in the familial breast cancer cases, frequencies of Arg72Arg, Arg72Pro and Pro72Pro were 53.4%, 34.2% and 12.3%, respectively. In sporadic breast cancer, 56.0%, 34.9% and 9.1% were homozygous for 72Arg allele, heterozygous and homozygous for 72Pro allele, respectively. No statistically significant associations were found between the TP53 Arg72Pro polymorphism and risk of familial and sporadic breast cancer risk (Table 1).
###end p 26
###begin p 27
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg72Pro </italic>
###xml 18 31 18 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 Ins16bp </italic>
TP53 Arg72Pro and PIN3 Ins16bp genotypic and allelic frequencies. Association with familial and sporadic breast cancer risk.
###end p 27
###begin p 28
* OR adjusted for age (logistic regression analysis)
###end p 28
###begin p 29
FH - family history; OR - odds ratio; CI - confidence interval
###end p 29
###begin p 30
###xml 15 33 15 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 PIN3 Ins16bp </italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A1A1</italic>
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A1A2 </italic>
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2A2</italic>
###xml 247 250 247 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A1 </italic>
###xml 290 293 290 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2 </italic>
###xml 332 337 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2A2 </italic>
###xml 565 570 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2A2 </italic>
###xml 708 713 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2A2 </italic>
Frequencies of TP53 PIN3 Ins16bp polymorphism genotypes were 65.7% to A1A1, 21.4% to A1A2 and 12.9% to A2A2, in familial breast cancer cases. Regarding sporadic breast cancer group, we observed 63.9%, 29.3% and 6.8% frequencies for homozygous for A1 allele, heterozygous and homozygous for A2 allele, respectively. We observed that A2A2 genotype carriers with positive FH were at a 4.40-fold (95% CI = 1.60-12.0; p = 0.004) increased risk of breast cancer compared with the respective control group. Moreover, statistically significant differences were observed in A2A2 genotype frequencies comparing sporadic breast cancer cases and respective control group (p = 0.026). Our results showed that carriers of A2A2 genotype with no FH present an increased risk of breast cancer (OR = 3.88, 95% CI 1.18-12.8).
###end p 30
###begin p 31
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 120 132 120 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg-A1 </italic>
###xml 243 255 243 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg-A2 </italic>
###xml 360 372 360 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg-A2 </italic>
We investigated haplotype effects of the two polymorphisms studied in breast cancer risk (Table 2). Compared the common TP53 Arg-A1 haplotype with the other expected haplotypes; we only observed statistically significant differences regarding TP53 Arg-A2 haplotype between the familial breast cancer cases and respective control group (p = 0.028). Carriers of TP53 Arg-A2 haplotype and presence of FH of breast cancer presented an increased risk of develop breast cancer (OR= 2.10; 95% CI 1.08-4.06).
###end p 31
###begin p 32
###xml 39 48 39 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Pro </italic>
###xml 52 65 52 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 Ins16bp </italic>
Expected haplotype frequencies between Arg72Pro and PIN3 Ins16bp polymorphisms. Association with familial and sporadic breast cancer risk.
###end p 32
###begin p 33
FH - family history; OR - odds ratio; CI - confidence interval
###end p 33
###begin p 34
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2A2 </italic>
###xml 233 238 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A1A1 </italic>
###xml 242 247 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A1A2 </italic>
###xml 389 394 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2A2 </italic>
###xml 488 491 482 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A1 </italic>
###xml 642 650 636 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pro/Pro </italic>
###xml 715 724 709 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Pro </italic>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
###xml 630 638 <span type="species:ncbi:9606">patients</span>
We examined the relationship between age at onset and genotypes and found a positive correlation in the FH group. The mean age of FH patients group with A2A2 genotype was 33.43 (+/- 8.08) years, whereas the mean age of patients with A1A1 and A1A2 genotypes was 42.44 (+/- 12.14) and 44.80 (+/- 10.85) years, respectively (Kruskal Wallis test p = 0.056). Therefore, the carrier's status of A2A2 genotype was associated with an earlier age at onset cancer with respect to the patients with A1 genotypes. However, this difference was in the frontier of statistically significant, possibly because of the smaller size of the group (7 patients to Pro/Pro genotype). No association was observed relating age at onset and Arg72Pro polymorphism (Kruskal Wallis test p = 0.747).
###end p 34
###begin p 35
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pro </italic>
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2 </italic>
The analysis of the TP53 polymorphisms with respect to some clinical pathological showed a significant association of Pro or A2 genotypes with the presence of lymph node metastases (p = 0.009 and p < 0.001, respectively, adjusted for age and breast cancer family history, using logistic regression analysis).
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
Breast cancer is an heterogeneous disease, as sustained by wide variable morphological appearance, many risks factors and distinct gene expression profile [2,22]. Common genetic alterations (e.g. polymorphisms), with possible effects on function and/or protein expression, within genes involved in essential cellular pathways, such as carcinogen metabolism, DNA repair, cell cycle control and cell proliferation, could predispose individuals to cancer [15,23-25], including breast cancer [15,26-29].
###end p 37
###begin p 38
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
The TP53 is one of the major tumour suppressor genes which carry out essential functions in preservation of genome integrity. Thus, when the cell is under stress, particularly stress which will involve DNA damage, p53 promotes growth arrest, allowing the cell to repair the DNA lesions. If the damage is excessively hazardous, then p53 will lead to cell apoptosis. Several genetic polymorphisms have been described in TP53 gene [18] and some of these variants seem to confer different functions among the p53 [30-32].
###end p 38
###begin p 39
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 68 77 68 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Pro </italic>
###xml 81 93 81 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 Ins16bp</italic>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 432 441 432 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Pro </italic>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
In the present study, we evaluated two separate TP53 polymorphisms, Arg72Pro and PIN3 Ins16bp, in two groups of breast cancer, familial and sporadic cases, as well as in matching control groups. The allelic frequencies of our control group for the different polymorphisms are in accordance with earlier reports from European populations [16,33]. We found a deviation from Hardy-Weinberg equilibrium in overall group of controls for Arg72Pro P53 polymorphism genotypes. Hardy-Weinberg equilibrium depends on a series of features about the tested population, including, for example the sample population size, random mating, no migration, no genetic drift and no selection taking place [34]. Thus, this deviation could be due to chance or violation of these assumptions, being the possibility of genotyping errors lower, since 10% our control sample genotyping were confirmed by direct sequence and its were similar with other European populations.
###end p 39
###begin p 40
###xml 15 29 15 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">codon 72 TP53 </italic>
###xml 43 52 43 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg72Pro)</italic>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 337 348 337 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 72Pro </italic>
###xml 411 422 411 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 72Arg </italic>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 483 494 483 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 72Pro </italic>
###xml 539 545 539 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">72Arg </italic>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 582 593 582 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 72Arg </italic>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 779 781 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 829 843 829 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg72Pro </italic>
###xml 880 891 880 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 72Pro </italic>
###xml 917 922 917 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1021 1027 1021 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">72Arg </italic>
###xml 1053 1055 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1177 1186 1177 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1224 1238 1224 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg72Pro </italic>
Concerning the codon 72 TP53 polymorphism (Arg72Pro), we did not find any association between this polymorphism and breast cancer. Our results are in agreement with other studies [33,35,36], however, the literature remains highly controversial regarding the role of this polymorphism in breast cancer risk [37-42]. One study showed that TP53 72Pro variant induces transcription activation more efficiently than TP53 72Arg variant [40]. On the other hand, other authors revealed that TP53 72Pro variant induce cell cycle arrest better than 72Arg [31]. Other studies have showed that TP53 72Arg variant is more efficient in inducing apoptosis [32,42]. Beside apoptosis and cell cycle control, p53 protein seems to be crucial in the regulation of the different DNA repair pathways [43]. A recent study demonstrated the influence of TP53 Arg72Pro in DNA repair capacity, showing that TP53 72Pro variant activates several TP53 dependent target genes involved in DNA repair and DNA damage repair much more efficiently than the 72Arg variant expressing cells [30]. These contradictory results could be explained by the differential effects of this alteration in p53 function. Several in vitro evidences have demonstrated that both TP53 Arg72Pro variants may selectively regulate specific cellular functions.
###end p 40
###begin p 41
###xml 3 13 3 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 PIN3 </italic>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2A2 </italic>
###xml 400 408 400 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 A2 </italic>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 487 505 487 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 PIN3 Ins16bp </italic>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 805 813 805 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 A2 </italic>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 119 124 <span type="species:ncbi:9606">women</span>
In TP53 PIN3 polymorphism, our findings suggest an association of A2A2 genotype and increased breast cancer risk among women with FH and sporadic breast cancer, suggesting that this polymorphism contributed to enhance susceptibility for breast cancer among Portuguese population, regardless of the presence of FH. Our results are supported by previously reported studies suggesting an association of PIN3 A2 genotypes with breast cancer risk [44]. Although, the biological effect of the TP53 PIN3 Ins16bp polymorphism is currently unclear, theoretically, this polymorphism could affect mRNA splicing, altering the coding regions and therefore being implicated in regulation of gene expression and DNA-protein interactions, resulting in a defective protein [45,46]. Until now, just a single study had show PIN3 A2 allele presents reduced mRNA stability [47].
###end p 41
###begin p 42
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 366 373 366 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg-A2 </italic>
###xml 503 510 503 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pro-A1 </italic>
###xml 582 588 582 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 689 696 689 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg-A2 </italic>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 810 813 810 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2 </italic>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 887 889 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 422 427 <span type="species:ncbi:9606">women</span>
The linkage disequilibrium between TP53 polymorphisms region could be an important factor affecting the incidence of cancer in general [48,49], and breast cancer, in particular [42,44,50]. Thus, haplotype analysis would be important to confirm the significance of this variant on breast cancer susceptibility. A statistical significant association was found between Arg-A2 haplotype and breast cancer susceptibility among women with FH of breast cancer. On the other hand, a recent study has found that Pro-A1 haplotype individuals present increased breast cancer risk, however, in BRCA2 mutation carriers [42]. Nevertheless, other reports have also demonstrated a positive association of Arg-A2 haplotype with cancer [44,48]. Moreover, functional studies have shown that, in a specific haplotype combination, A2 allele is associated with decreased apoptotic and DNA repair capacity [33,48].
###end p 42
###begin p 43
###xml 25 33 25 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pro/Pro </italic>
###xml 37 47 37 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A2A2 TP53 </italic>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
Our findings suggest the Pro/Pro and A2A2 TP53 genotypes as predictor factors for the presence of lymph node metastases, being in agreement with previously functional studies in the biological consequences of these variations in P53 protein functions [40,47].
###end p 43
###begin p 44
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 419 424 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 563 581 563 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 PIN3 Ins16bp </italic>
The natural history of breast cancer can be influenced by several factors. We hypothesize that under the influence of TP53 genetic polymorphisms, chronic exposure to higher levels of several endogenous (e.g. estrogens) and exogenous breast carcinogens resulting in consequent higher accumulation of DNA damage during an individual's lifetime, may alter the age at onset of disease. Moreover, it has been suggested that TP53 polymorphisms are associated to familial breast cancer by the age of 50 years [33]. Our results are consistent with this hypothesis, since TP53 PIN3 Ins16bp polymorphism seems to influence directly the age to onset of familial breast cancer.
###end p 44
###begin title 45
Conclusion
###end title 45
###begin p 46
###xml 36 54 36 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 PIN3 Ins16bp </italic>
###xml 337 349 337 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/BRCA2 </italic>
###xml 394 408 394 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 Arg72Pro </italic>
###xml 412 425 412 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIN3 Ins16bp </italic>
In conclusion, our findings suggest TP53 PIN3 Ins16bp polymorphism as a real risk modifier in breast cancer disease, either in sporadic and familial breast cancer. Subsequently, these results will be crucial in the characterization of the genetic breast cancer susceptibility profile, within familial breast cancer cases non-carriers of BRCA1/BRCA2 mutations. Furthermore, our findings suggest TP53 Arg72Pro and PIN3 Ins16bp polymorphisms as predictive factors of presence of lymph node metastases.
###end p 46
###begin title 47
Abbreviations
###end title 47
###begin p 48
FH: Family history; PCR: Polymerase chain reaction; RFLP: Restriction fragment length polymorphism; OR: Odds ratio; CI: Confidence interval; OS: Estimate overall survival.
###end p 48
###begin title 49
Competing interests
###end title 49
###begin p 50
The author(s) declare that they have no competing interests.
###end p 50
###begin title 51
Authors' contributions
###end title 51
###begin p 52
The SC was the principal investigator; contribute to data and samples collection, developed study design, experimental plan and implementation, statistical analysis, and drafted the manuscript. DP contributed to data and samples collection and critical revision of the manuscript. DP, HR and JCT were critical to data and samples collection. RM contributed to study design, samples collection, data analysis and critical review of the manuscript. FS contributed to conception of the study hypotheses, study design and critical review of the manuscript. In addition, all the authors read and approved the final submitted manuscript.
###end p 52
###begin title 53
Pre-publication history
###end title 53
###begin p 54
The pre-publication history for this paper can be accessed here:
###end p 54
###begin p 55

###end p 55
###begin title 56
Acknowledgements
###end title 56
###begin p 57
The authors would like to thank to Oncology and Surgical Department from S. Joao Hospital at Porto, and the Pathology Departments of the different Hospitals involved. We would like to thank to Imunohemotherapy Department of S. Marcos Hospital at Braga and to Clinica Laboratorial Dr. Edgar Botelho Moniz for their helpful assistance in the management of controls. We gratefully acknowledge FLAD (Fundacao Luso-Americana para o Desenvolvimento), the Minister of Health of Portugal (Comissao de Fomento da Investigacao em Cuidados de Saude: CFICS- 226/01), Astra Zeneca Foundation and Calouste Gulbenkian Foundation by financial funding of this work. We also gratefully acknowledge the Minister of Science and Superior Education-FCT (Fundacao para a Ciencia e Tecnologia: SFRH/BD/9758/2003) by financial support of individual grant for Doctoral degree of the first author.
###end p 57
###begin article-title 58
Perspectives on the chemical etiology of breast cancer
###end article-title 58
###begin article-title 59
Understanding breast cancer risk -- where do we stand in 2005?
###end article-title 59
###begin article-title 60
Breast cancer susceptibility and the DNA damage response
###end article-title 60
###begin article-title 61
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium
###end article-title 61
###begin article-title 62
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
###end article-title 62
###begin article-title 63
Mutational spectrum of p53 mutations in primary breast and ovarian tumors
###end article-title 63
###begin article-title 64
TP53 mutations in familial breast cancer: functional aspects
###end article-title 64
###begin article-title 65
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype
###end article-title 65
###begin article-title 66
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
###end article-title 66
###begin article-title 67
BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest
###end article-title 67
###begin article-title 68
###xml 90 98 <span type="species:ncbi:9606">patients</span>
p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer
###end article-title 68
###begin article-title 69
###xml 14 22 <span type="species:ncbi:9606">patients</span>
Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival
###end article-title 69
###begin article-title 70
###xml 102 107 <span type="species:ncbi:9606">human</span>
Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer
###end article-title 70
###begin article-title 71
###xml 76 81 <span type="species:ncbi:9606">human</span>
Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer
###end article-title 71
###begin article-title 72
HER2 polymorphism and breast cancer risk in Portugal
###end article-title 72
###begin article-title 73
Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer
###end article-title 73
###begin article-title 74
The IARC TP53 database: new online mutation analysis and recommendations to users
###end article-title 74
###begin article-title 75
Polymorphisms in the p53 pathway
###end article-title 75
###begin article-title 76
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium
###end article-title 76
###begin article-title 77
###xml 54 62 <span type="species:ncbi:9606">patients</span>
[Analysis of mutations in genes BRCA1 and BRCA2 among patients with breast and ovarian cancer in northern Portugal and Galicia]
###end article-title 77
###begin article-title 78
A method for assessing disease associations with SNP haplotypes and environmental variables in case-control
###end article-title 78
###begin article-title 79
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 79
###begin article-title 80
Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms
###end article-title 80
###begin article-title 81
Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population
###end article-title 81
###begin article-title 82
Importance of xeroderma pigmentosum group D polymorphisms in susceptibility to ovarian cancer
###end article-title 82
###begin article-title 83
###xml 64 69 <span type="species:ncbi:9606">women</span>
Catechol-O-methyltransferase haplotypes and breast cancer among women on Long Island, New York
###end article-title 83
###begin article-title 84
Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages
###end article-title 84
###begin article-title 85
###xml 89 97 <span type="species:ncbi:9606">patients</span>
DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil
###end article-title 85
###begin article-title 86
Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk
###end article-title 86
###begin article-title 87
Trp53-dependent DNA-repair is affected by the codon 72 polymorphism
###end article-title 87
###begin article-title 88
p53 polymorphic variants at codon 72 exert different effects on cell cycle progression
###end article-title 88
###begin article-title 89
The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
###end article-title 89
###begin article-title 90
Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years
###end article-title 90
###begin article-title 91
###xml 113 121 <span type="species:ncbi:9606">patients</span>
No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients
###end article-title 91
###begin article-title 92
Evidence against involvement of p53 polymorphism in breast cancer predisposition
###end article-title 92
###begin article-title 93
###xml 161 169 <span type="species:ncbi:9606">Patients</span>
Retention of the p53 Codon 72 Arginine Allele Is Associated with a Reduction of Disease-Free and Overall Survival in Arginine/Proline Heterozygous Breast Cancer Patients
###end article-title 93
###begin article-title 94
###xml 74 79 <span type="species:ncbi:9606">women</span>
The R72P P53 mutation is associated with familial breast cancer in Jewish women
###end article-title 94
###begin article-title 95
P53 codon 72 polymorphism in breast cancer
###end article-title 95
###begin article-title 96
Two polymorphic variants of wild-type p53 differ biochemically and biologically
###end article-title 96
###begin article-title 97
Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?
###end article-title 97
###begin article-title 98
A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers
###end article-title 98
###begin article-title 99
p53: traffic cop at the crossroads of DNA repair and recombination
###end article-title 99
###begin article-title 100
p53 haplotype determination in breast cancer
###end article-title 100
###begin article-title 101
Introns: evolution and function
###end article-title 101
###begin article-title 102
Rna Regulation: a new genetics?
###end article-title 102
###begin article-title 103
A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA
###end article-title 103
###begin article-title 104
p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity
###end article-title 104
###begin article-title 105
P53 polymorphisms and haplotypes in lung cancer
###end article-title 105
###begin article-title 106
p53 polymorphisms and haplotypes in breast cancer
###end article-title 106

